Trump administration will allow pharmacies to make popular peptides

The Department of Health and Human Services will not pursue enforcement against small compounding pharmacies that make six peptides popular in wellness circles: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. The substances have not been approved by the Food and Drug Administration, and evidence for their safety and effectiveness is sparse. Their promoters claim benefits ranging from wound healing and better metabolic health to relief from insomnia, migraines and ulcerative colitis. Until now, people seeking them have often turned to online gray-market sellers, including overseas suppliers of products labeled for research use. The policy creates a route to obtain the peptides through regulated pharmacies, but does not change their legal status or amount to FDA approval.

The change applies only to smaller 503A pharmacies, not larger outsourcing facilities, and production may be slow and limited. One pharmacy executive said his company may make only one peptide and would be unable to meet demand; pharmacies and ingredient suppliers also need to verify that ingredients meet policy requirements. Compounding supporters say pharmacy oversight and adverse-event reporting offer patients a more accountable alternative to illicit products. Critics argue that allowing unproven drugs without the usual FDA review risks contamination, other adverse effects and weakened regulatory safeguards. FDA scientists had opposed loosening restrictions, despite an advisory panel’s July support for expanded access, and consumer advocates say the administration bypassed the standard process for changing policy.